Navigation Links
Stereotaxis Announces FDA Approval of Its Partnered Magnetic Irrigated Catheter
Date:1/15/2008

Important Milestone for Treatment of Complex Arrhythmias Achieved

Approval Considered Transformative for Stereotaxis Business Model

ST. LOUIS, Jan. 15 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) announced today that the Company has been advised that the U.S. Food and Drug Administration (FDA) has approved its partnered magnetic irrigated catheter for use in mapping and ablation in the United States.

"The long-awaited FDA approval of our partnered irrigated catheter is a very significant milestone for Stereotaxis," said Bevil J. Hogg, Chief Executive Officer of Stereotaxis. "Since its approval and introduction in Europe, the irrigated catheter has been used to successfully treat complex left-sided arrhythmias at a number of leading hospitals in Europe. Patient outcomes have been excellent. The Stereotaxis Magnetic Navigation System, used in conjunction with the magnetic irrigated catheter and the Company's latest software release has performed extremely well with a high degree of safety. We believe that these results will be duplicated at centers in the U.S., and we are confident that the Stereotaxis Magnetic Navigation System with the irrigated catheter has the potential to establish a new standard of care in the treatment of complex arrhythmias. A broad spectrum of thought leaders will present their initial experience with the magnetic irrigated catheter in European centers during the Boston Atrial Fibrillation Symposium on January 17 and 18, and we eagerly look forward to their presentations.

"There is significant pent-up demand for our solution among both existing and prospective customers," continued Mr. Hogg. "As a result, once the irrigated catheter becomes broadly available in the U.S., we anticipate a return to strong pipeline and order growth for our Magnetic Navigation System and accelerated growth in usage rates and related recurring revenues. We are highly confident that this momentum will be transformative for our company."

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe and Canada.

About Forward Looking Statements

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that we will recognize revenue related to our purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of our control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.


'/>"/>
SOURCE Stereotaxis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Stereotaxis Niobe System Used to Perform More Than 10,000 Procedures Worldwide
2. Healthcare Technologies Ltd. (NASDAQ: HCTL) Announces Extension of Letters of Intent to Acquire Majority Interest in Two Ethanol Plants
3. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
4. Hagens Berman Sobol Shapiro Announces Proposed Class-Action Lawsuit Against CellCyte
5. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
6. Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend
7. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
8. The Wisconsin Heart Hospital Announces Live Webcast Demonstrating Breakthrough Device to Facilitate Beating Heart and Robotic Coronary Revascularization Surgery
9. HealthCare Technologies Ltd. (NASDAQ: HCTL) Announces Receipt of NASDAQ Delisting Notice
10. Elekta Announces Clinical Start-up of Elekta Synergy(R) S at UPMC
11. Pharsight Announces Fiscal Third Quarter 2008 Earnings Release Date and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration ... at the 5th Annual Marcum MicroCap Conference on Thursday, June ... at the Grand Hyatt Hotel. The Company,s presentation ... scheduled to begin at 11a.m ET in the Broadway Room. ... and outline milestones for the balance of 2016 and beyond. ...
(Date:5/26/2016)... San Diego, CA (PRWEB) , ... May 26, ... ... assay development and manufacturing company, today announced several positive developments that position the ... As a result of the transaction, Craig F. Kinghorn has been appointed ...
(Date:5/25/2016)... ... May 25, 2016 , ... Thailand’s Board of Investment’s New ... San Francisco. Located at booth number 7301, representatives from the Thai Government, research ... the Thai biotechnology and life sciences sector. , Deputy Secretary General of ...
(Date:5/25/2016)... Bethesda, Md. (PRWEB) , ... May 25, 2016 ... ... a request for information (RFI) issued by the Office of the National Coordinator ... the patient experience, and determines if clinically relevant data were available when and ...
Breaking Biology Technology:
(Date:3/14/2016)... 2016 NXTD ) ("NXT-ID" or the ... announces the airing of a new series of commercials on ... March 21 st .  The commercials will air on Bloomberg ... on the Street show. --> NXTD ) ("NXT-ID" ... commerce market, announces the airing of a new series of ...
(Date:3/11/2016)... 11, 2016 http://www.apimages.com ) - --> ... is available at AP Images ( http://www.apimages.com ) - ... used to produce the new refugee identity cards. DERMALOG will be ... CeBIT in Hanover next week.   --> ... be used to produce the new refugee identity cards. DERMALOG will ...
(Date:3/10/2016)... 2016 --> ... "Identity and Access Management Market by Component (Provisioning, Directory ... by Organization Size, by Deployment, by Vertical, and by ... The market is estimated to grow from USD 7.20 ... at a Compound Annual Growth Rate (CAGR) of 12.2% ...
Breaking Biology News(10 mins):